Abstract 581P
Background
Afatinib is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that is widely used to treatfor EGFR-mutated non-small cell lung cancer (NSCLC). The association between afatinib-related adverse events (AEs) and survival outcomes in patients with NSCLC has been rarely reported.
Methods
We retrospectively reviewed treatment-naȉive patients with NSCLC treated with afatinib for ≥1 month at Chang Gung Memorial Hospital. We analyzed the association between different types of AEs and clinical outcomes, including progression-free survival (PFS) and overall survival (OS).
Results
This study included 599 patients. The patients who experienced any grades of AEs had longer OS (median OS = 27.2 vs. 14.0 months, p = 0.019) than those who did not. As for PFS did not differ significantly between these two groups. Regarding the types of AE, the patients with either paronychia (median PFS =, 16.0 vs. 12.4 months, p = 0.011), skin lesions (median PFS =, 15.4 vs. 12.1 months, p = 0.042), or gastrointestinal (GI) symptoms, including nausea/vomiting (median PFS =, 18.8 vs. 14.3 months, p = 0.016), had experienced significantly better PFS than patients without these AEs. In addition, the patients with either paronychia (median OS =, 31.0 vs. 21.0 months, p < 0.001), skin lesions (median OS =, 29.3 vs. 20.9 months, p < 0.001), pruritus (median OS =, 31.6 vs. 24.7 months, p < 0.001), or mucositis/oral ulcers (median OS =, 30.2 vs. 25,5 months, p < 0.023) had showed better OS than patients without these AEs. After adjustment, the patients with experiencing paronychia and GI symptoms had favorable PFS, and those with paronychia, skin lesions, pruritus, or mucositis/oral ulcers had favorable OS.
Conclusions
Patients with NSCLC treated with patients undergoing afatinib and experiencing adverse events (AEs) had favorable survival PFS and OS. In addition, the associations between afatinib-related AEs and survival outcomes were type-dependent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract